Effect of Extraesophageal Reflux on Inferior Nasal Turbinates Hypertrophy

Sponsor
University Hospital Ostrava (Other)
Overall Status
Recruiting
CT.gov ID
NCT04581174
Collaborator
University Hospital Bratislava (Other), Fortmedica Prague (Other)
160
3
4
11.5
53.3
4.6

Study Details

Study Description

Brief Summary

The study examines the severity of extraesophageal reflux using oropharyngeal pH monitoring in patients with varying degrees of lower turbinates hypertrophy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
N/A

Detailed Description

Hypertrophy of the lower turbinates causes obstruction of the nasal breathing with several health risks and a significant reduction in quality of life. Mouth breathing is non-physiological. When breathing through the mouth, the air is not purified, warmed, or humidified. This results in more frequent respiratory infections, drying of the airways, burning in the throat and causes snoring and sleep apnoea overnight. Also, nasal obstruction leads to a significant reduction in quality of life. Conservative treatment with topically applied corticosteroids is often without effect and surgical reduction of the lower turbinates under local or general anesthesia is necessary. The operation is another discomfort for the patient and is not without risks.

The pathogenesis of lower turbinates hypertrophy is multifactorial. Currently, extraesophageal reflux (EER) is considered to be a possible factor as well. The role of EER in chronic rhinosinusitis, especially in difficult-to-treat conditions, has been investigated in the past, and EER would likely be a possible co-factor. The relationship between hypertrophic lower turbinates and EER has not been studied yet.

The primary outcome/goal of the study:

To examine the severity of extraesophageal reflux using oropharyngeal pH monitoring in patients with varying degrees of lower turbinates hypertrophy.

Other goals:
  • To compare extraesophageal reflux severity in patients with posterior inferior turbinate hypertrophy.

  • To evaluate the difference between anterior and posterior hypertrophy of the inferior turbinates in patients with proven extraesophageal reflux.

  • To evaluate the lateral difference of lower turbinates hypertrophy in patients with proven EER and in patients without proven EER.

Study protocol:
  • anamnestic questionnaire (age, sex, weight, height, smoking, alcohol, reflux disease, treatment with topical corticosteroids, treatment of reflux disease)

  • Reflux Symptom Index (RSI) questionnaire

  • Sino-Nasal Outcome Test (SNOT 22) questionnaire

  • rhinomanometry (optional - if available)

  • acoustic rhinometry (optional - if available)

  • olfactory questionnaire (optional - if available)

  • endoscopy of the nasal cavity with evaluation:

  • of the degree of hypertrophy of the lower turbinates according to Camacho, 2014 (for both turbinates separately and separately anterior and posterior half of the turbinates) (attachment 1)

  • of bulky posterior inferior turbinate hypertrophy

  • of reddening of the posterior ends of the lower turbinates

  • of reddening of nasopharynx

  • 24-hour monitoring of oropharyngeal pH by Restech, RYAN score upright and supine and pH values <5.5 will be evaluated

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study subjects will be enrolled to a total of four study arms, depending on the degree of inferior turbinates hypertrophy (according to Camacho)The study subjects will be enrolled to a total of four study arms, depending on the degree of inferior turbinates hypertrophy (according to Camacho)
Masking:
None (Open Label)
Masking Description:
No masking is being used in this study
Primary Purpose:
Diagnostic
Official Title:
Effect of Extraesophageal Reflux on Inferior Nasal Turbinates Hypertrophy
Actual Study Start Date :
Oct 15, 2020
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Oct 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1st degree of hypertrophy according to Camacho

Patients with 1st degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Diagnostic Test: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Experimental: 2nd degree of hypertrophy according to Camacho

Patients with 2nd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Diagnostic Test: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Experimental: 3rd degree of hypertrophy according to Camacho

Patients with 3rd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Diagnostic Test: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Experimental: 4th degree of hypertrophy according to Camacho

Patients with 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Diagnostic Test: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.

Outcome Measures

Primary Outcome Measures

  1. Severity of extraesophageal reflux using oropharyngeal pH monitoring [24 hours]

    The primary outcome measure of the study is to examine the severity of extraesophageal reflux using oropharyngeal pH monitoring in patients with varying degrees of lower turbinates hypertrophy, assessed on the RYAN score.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age 18-80 years

  • patients indicated for oropharyngeal pH-metry (Restech) with suspected extraesophageal reflux

  • patients with 2nd - 4th degree hypertrophy of the lower turbinates (according to Camacho Classification)

Exclusion Criteria:
  • patients with chronic rhinosinusitis with polyps

  • patients who have had an acute upper respiratory tract infection in the last 8 weeks

  • patients after previous surgery in the nasal cavity and nasopharynx

  • patients after radiotherapy in the head and neck area

  • non tolerance of pH catheter

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Ostrava Ostrava Moravian-Silesian Region Czechia 70852
2 Fortmedica Prague Praha Czechia 14300
3 Comenius University, University Hospital Bratislava Bratislava Slovakia 85107

Sponsors and Collaborators

  • University Hospital Ostrava
  • University Hospital Bratislava
  • Fortmedica Prague

Investigators

  • Principal Investigator: Karol Zeleník, Ass.Prof.,MD,PhD, University Hospital Ostrava

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital Ostrava
ClinicalTrials.gov Identifier:
NCT04581174
Other Study ID Numbers:
  • FNO-ENT-turbinates_hypertrophy
First Posted:
Oct 9, 2020
Last Update Posted:
Feb 23, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital Ostrava
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2021